コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 rylation on its activator T loop in vitro by Aurora A.
2 otein ALADIN is a novel spatial regulator of Aurora A.
3 in part by a kinase-independent function of Aurora A.
4 activation, independently of the effects of Aurora A.
5 latter defect was also rescued by inhibiting Aurora A.
6 inhibition of another 49 kinases, including Aurora A.
7 a DFG conformation change at the ATP site of Aurora A.
8 is significantly reduced upon inhibition of Aurora A.
9 veloped to target specific subpopulations of Aurora A.
10 activation towards its centrosomal substrate Aurora A.
11 D pathogenesis involving failure to activate Aurora-A.
12 ance and ERalpha is a bona fide substrate of Aurora-A.
13 kdown of USP2a reduced the protein levels of Aurora-A.
14 c progression by regulating the stability of Aurora-A.
15 role of USP2a in mediating the stability of Aurora-A.
16 on impairs activating autophosphorylation of Aurora A, a cell-cycle kinase critical for meiotic trans
18 rt the discovery of a selective inhibitor of Aurora A, a key regulator of cell division and potential
21 reveal a potential mechanistic link between Aurora A activation and changes in the intracellular red
23 that a conserved cysteine residue within the Aurora A activation loop is crucial for Aurora A activat
26 alysis, we propose a revised, fluid model of Aurora-A activation in which the first step is a reducti
29 s both INCENP and Aurora B activity (but not Aurora A activity) and is critical for Polo function at
31 hich the CHK2-BRCA1 axis restrains oncogenic Aurora-A activity during mitosis and identify BRCA1 itse
32 lation of BRCA1 leads to increased oncogenic Aurora-A activity, which acts as a mediator for abnormal
34 stabilization mechanism in which binding to Aurora-A alters how N-Myc interacts with SCF(FbxW7) to d
39 ors that disrupts the native conformation of Aurora A and drives the degradation of MYCN protein acro
42 rotein, such as small-molecule inhibitors of Aurora A and mTOR, are currently being evaluated in earl
43 protein was overexpressed concurrently with Aurora A and NF-kappaB signaling factors in patients wit
46 propose that Gravin-mediated recruitment of Aurora A and Plk1 to the mother (oldest) spindle pole co
47 tion of stathmin knockdown and inhibition of Aurora A and Plk1 was not additive and again delayed mit
50 e, we monitor the phosphorylation of Bora by Aurora A and Plk1, analyzing the generated distinctive p
52 otein Gravin/AKAP12 and the mitotic kinases, Aurora A and Plk1, that is down regulated in human semin
56 ially overlapping, nonredundant functions of Aurora A and Plk4 kinases contribute to initiate acentri
59 further demonstrate that the mitotic kinases Aurora-A and -B phosphorylate KIBRA both in vitro and in
61 interaction between the catalytic domain of Aurora-A and a site flanking Myc Box I that also binds S
63 SMAD5, indicating a novel interplay between Aurora-A and SMAD5 signaling pathways in the development
64 the crystal structure of the complex between Aurora-A and this region of N-Myc to 1.72-A resolution.
65 t not BRAF, associates with Aurora kinase A (Aurora-A) and Polo-like kinase 1 (Plk1) at the centrosom
67 , and cyclin B1 and phosphorylation of PLK1, Aurora A, and TPX2 were rescued by inhibition of the ana
68 ch can individually increase the activity of Aurora-A, and the effect of both bound together is the e
70 ons because it highlights the mitotic kinase Aurora-A as a novel promising therapeutic target to sele
71 ogues p37/p47 resulted in an accumulation of Aurora A at centrosomes and a delay in centrosome separa
75 al delivery of Polo-like kinase 1 (Plk1) and Aurora A (AurA) inhibitors attenuates kinase activity, p
78 ulatory allosteric pocket of the oncoprotein Aurora A (AurA) kinase, thereby offering the potential f
79 HEF1 scaffold and activating its associated Aurora-A (AurA), a kinase crucially required for primary
81 nce-inducing inhibitor of the mitotic kinase Aurora A (AURKA) with an MDM2 antagonist activates p53 i
83 ed during cancer progression, interacts with Aurora-A (AURKA) kinase to control ciliary resorption, a
84 pment and homeostasis, we interbred a floxed Aurora-A (Aurora-A(fl)) mouse with the Cre-deleter strai
85 ch was associated with delayed activation of Aurora A, Aurora B, and cyclin-dependent kinase 1 (CDK1)
87 s led to SAR156497, an exquisitely selective Aurora A, B, and C inhibitor with in vitro and in vivo e
95 e, our results suggest that unphosphorylated Aurora-A bound to the mitotic spindle by TPX2 is catalyt
96 important not only for the activity of human Aurora A but also for that of fission yeast MAPK-activat
97 ation process of the serine/threonine kinase Aurora-A by phosphorylation and by its protein partner,
101 tudies and biochemical assays, delineates an Aurora A conformation-specific effect on proteolytic deg
102 teric activation by TPX2 of dephosphorylated Aurora A could be at play in the spindle microtubules.
103 Furthermore, our data also illustrated that Aurora-A could not only induce mRNA and protein expressi
105 vels of apoptosis or senescence, but because Aurora-A-deficient tumors accumulate polyploid cells wit
106 bitor, suggesting a centrosomal role for the Aurora A-dependent complex of clathrin, ch-TOG, and TACC
110 Using in vitro kinase assays, we show that Aurora A directly phosphorylates YY1 at serine 365 in th
112 A1 tumor suppressor axis restrains oncogenic Aurora-A during mitosis to ensure karyotype stability re
113 ssion of Aurora-A decreases and depletion of Aurora-A enhances tamoxifen sensitivity in ERalpha-posit
115 and polyploid keratinocytes were evident in Aurora-A(-/-) epidermis, indicating that a deficiency in
116 ferentiation marker keratin 1 was evident in Aurora-A(-/-) epidermis, there was a marked reduction in
120 homeostasis, we interbred a floxed Aurora-A (Aurora-A(fl)) mouse with the Cre-deleter strain, K14.Cre
126 pyrimidine 1 was identified as a potent hit (Aurora A IC(50) = 6.1 +/- 1.0 nM) from in-house screenin
130 and suggest therapeutic use from inhibiting Aurora A in head and neck cancers, which overexpress BMI
134 ts uncover a novel mechanism that implicates Aurora A in the mitotic inactivation of transcription fa
136 I1/hSNF5 leads to aberrant overexpression of Aurora A in these tumors, which is required for their su
138 lized in neuroblastoma by the protein kinase Aurora-A in a manner that is sensitive to certain Aurora
145 structure indicates that the conformation of Aurora-A induced by compounds such as alisertib and CD53
149 imized by structure-based design to a potent Aurora A inhibitor (IC50 = 2 nM) with very high kinome s
150 IBPR compounds as well as MLN8237, a proven Aurora A inhibitor, as chemical probes to investigate th
151 et in tamoxifen-resistant breast cancer, and Aurora-A inhibitor could be used as either an independen
153 so observed in glioma cells treated with the Aurora-A inhibitor TC-A2317 or anti-Aurora-A siRNA.
154 activity of Aurora-A, we show here that two Aurora-A inhibitors, MLN8054 and MLN8237, disrupt the Au
159 he as-AurA with 1-Na-PP1, we discovered that Aurora A is required for central spindle assembly in ana
163 active and that the phosphorylation state of Aurora-A is an inaccurate surrogate for its activity.
166 (27e), a potent inhibitor of Aurora kinases (Aurora-A K(d) = 7.5 nM, Aurora-B K(d) = 48 nM), FLT3 kin
172 We report here the design of the first human Aurora A kinase (as-AurA) engineered by chemical genetic
173 We established a conditional deletion of Aurora A kinase (AurA) in Cdk1 analogue-sensitive DT40 c
175 y activates the mitotic programme, including Aurora A kinase (Aurka), in stratified epithelia, and en
176 -throughput drug screening revealed that the Aurora A kinase (Aurora A)/Polo-like kinase 1 (PLK1)/cyc
181 ental Cell, Zhao et al. (2019) show that the Aurora A kinase AIR-1 is the long-sought cue that downre
182 over that C. elegans zygotes depleted of the Aurora A kinase AIR-1 or lacking centrosomes entirely us
183 eased expression of p53, reduced activity of aurora A kinase and a subsequent delay in the activation
184 rect ancestors of two colocalizing proteins, Aurora A kinase and its allosteric activator TPX2 (targe
186 cells showed reduced activation of Plk1 and Aurora A kinase at spindle poles and an impaired localiz
188 this study, x-ray crystal structures of the Aurora A kinase domain delineate redox-sensitive cystein
193 two MYCN-targeted small-molecule inhibitors, Aurora A kinase inhibitor alisertib (MLN8237) and mTOR i
195 olleagues demonstrate unequivocally that the Aurora A kinase inhibitor, alisertib, specifically neutr
197 agement of neuroendocrine prostate cancer as Aurora A kinase inhibitors promoting N-Myc destabilizati
199 copy, we have determined that phosphorylated Aurora A kinase is in dynamic equilibrium between a DFG-
201 oduce (18)O label into bacterially expressed Aurora A kinase phosphorylation sites and resulted in th
202 of p38, inositol trisphosphate 3-kinase, and Aurora A kinase potently enhance iPSC generation, and iP
203 ypertension drug felodipine to the oncogenic Aurora A kinase protein via hydrogen bonding interaction
205 tor YY1 as a novel mitotic substrate for the Aurora A kinase, a key regulator of critical mitotic eve
206 ic spindle formation and known substrates of Aurora A kinase, resulting in spindle assembly and cytok
209 Regulation of MCAK function is dependent on Aurora A kinase, which is regionally enhanced by signali
216 pharmacological and molecular inhibition of Aurora-A kinase activity restored a CD24(+) epithelial p
218 pindle assembly factor TPX2, which activates Aurora-A kinase and stimulates local microtubule nucleat
219 findings, our data clearly demonstrate that Aurora-A kinase does not regulate TACC3-chTOG complex fo
220 s show for the first time the causal role of Aurora-A kinase in the activation of EMT pathway respons
223 amics is spatially controlled through a Rac1-Aurora-A kinase pathway that locally inhibits the MT dep
226 n carcinoma cells, 28c and 40f inhibited the Aurora-A L215R and R220K mutants with IC50 values simila
229 to its activator protein TPX2, which impairs Aurora A localization at the mitotic spindle and induces
231 s embryos, centrosomes recruited more AIR-1 (Aurora A), matured precociously, and alignment of the mi
232 edox modulation of the conserved Cys(290) of Aurora A may be an underappreciated regulatory mechanism
239 ng induces stabilization and accumulation of Aurora-A mitotic kinase that ultimately drives the trans
240 Taken together, these results suggest that Aurora-A modulates the microtubule binding activity of H
243 inhibitors, MLN8054 and MLN8237, disrupt the Aurora-A/N-Myc complex and promote degradation of N-Myc
245 -deficient cells, as were phosphorylation of Aurora A on threonine 288, phosphorylation of Polo-like
251 By analyzing these mutants, we show that Aurora A phosphorylates the condensin I-dependent pool o
255 We further found that the Cep192-dependent Aurora A-Plk1 activity is essential for kinesin-5-mediat
257 screening revealed that the Aurora A kinase (Aurora A)/Polo-like kinase 1 (PLK1)/cyclin-dependent kin
258 late the activation/deactivation of Plk1 and Aurora A, possibly by linking them to mTOR signaling in
262 ay indicated that INI1/hSNF5 associates with Aurora A promoter in RT and normal cells but not in non-
263 ) epidermis, indicating that a deficiency in Aurora-A promotes aberrant mitosis, mitotic slippage, an
266 Taken together, our results suggest that the Aurora-A/Rap-1A pathway is associated with survival, tum
269 itosis, ATR localizes to centromeres through Aurora A-regulated association with centromere protein F
276 Moreover, aberrant expression of YAP and Aurora A signaling is highly correlated with triple-nega
278 CC3-chTOG complex formation, indicating that Aurora-A solely functions as a recruitment factor for th
282 k1 promotes phosphorylation of human Plk1 by Aurora A, suggesting that this mechanism is conserved in
284 s upstream activators polo-like kinase 1 and Aurora-A, targeted Hsp72 to the poles of cells with ampl
287 t an indirect regulatory mechanism involving Aurora A that may account for Gwl-dependent regulation o
288 ur results suggest that Wdr62 interacts with Aurora A to control mitotic progression, and loss of the
289 62 associates and genetically interacts with Aurora A to regulate spindle formation, mitotic progress
292 the catalytic activity of the Ser/Thr kinase Aurora A was inhibited by the oxidation of a conserved c
295 c does not require the catalytic activity of Aurora-A, we show here that two Aurora-A inhibitors, MLN
296 1-activated kinase and its downstream kinase Aurora A, which are critical regulators of centrosome ma
298 uppressor 2 (Lats2) on Ser(83) by activating Aurora-A, which controls Lats2 centrosome localization.
299 to inhibition by 28c and 40f compared to the Aurora-A wild type, suggesting that the T217 residue pla